
Gland Pharma gives Euro 20 Mn guarantee for Phixen SAS facility
The guarantee secures draw-downs and interest on an uncommitted Euro 50 Mn revolving facility with MUFG Bank, and runs until 31 Mar 2030.
- Agreement
- pharmaceuticals
Every Gland Pharma Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: agreement, earnings, management change.
3 articles · pharmaceuticals · Latest 12 Nov 2026

The guarantee secures draw-downs and interest on an uncommitted Euro 50 Mn revolving facility with MUFG Bank, and runs until 31 Mar 2030.

Gland Pharma (NSE: GLAND) reported consolidated total income of ₹1,902.60 crore and net profit of ₹290.80 crore for the quarter ended 30 Sep 2026, it said in a filing on 06 Nov 2026. Standalone total income was ₹1,473.20 crore and standalone net profit ₹293.50 crore for the same quarter.

Sahni takes the chief executive role from 2 Nov 2026 and will also be responsible for the Cenexi business, a wholly owned step-down subsidiary of the parent.